Inventiva Sa

Inventiva Sa Current Liabilities

The Current Liabilities of Inventiva Sa (IVA) as of Oct 16, 2026 is 85.74 M USD. In the previous year, Current Liabilities was 132.46 M USD — a change of -35.27% (lower).

Current Liabilities

85.74 MUSD

YoY

-35.27%

Last updated:

Current Liabilities of Inventiva Sa is 2025 85.74 M USD. Current Liabilities of Inventiva Sa was 2024 132.46 M USD. It decreases by -35.27% lower compared to the previous year.

The Inventiva Sa Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
14.04 M USD
Jan 1, 2019
12.37 M USD
Jan 1, 2020
14.80 M USD
Jan 1, 2021
24.72 M USD
Jan 1, 2022
32.38 M USD
Jan 1, 2023
59.21 M USD
Jan 1, 2024
132.46 M USD
Jan 1, 2025
85.74 M USD
The Inventiva Sa Current Liabilities history
YEARCurrent LiabilitiesYoY
85.74 MUSD-35.27%
132.46 MUSD+123.73%
59.21 MUSD+82.83%
32.38 MUSD+31.01%
24.72 MUSD+67.03%
14.80 MUSD+19.59%
12.37 MUSD-11.89%
14.04 MUSD+47.20%
9.54 MUSD+41.79%
6.73 MUSD+1.29%
6.64 MUSD+50.68%
4.41 MUSD+0.40%
4.39 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventiva Sa Stock analysis

What does Inventiva Sa do? Inventiva Sa is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Inventiva Sa is listed on the stock market with the ticker IVA and ISIN US46124U1079. It went public through an IPO on July 10, 2020. The company has 77 employees and operates within the Health Care sector. Its primary product development includes Lanifibranor, a peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. Additionally, the company is developing Odiparcil for mucopolysaccharidoses and has a pre-clinical program targeting TGF-ß for idiopathic pulmonary fibrosis. Inventiva Sa's website is https://inventivapharma.com. The company operates internationally, with its headquarters located in Daix, France. It is incorporated under French law, though the founding year is not specified in the provided information. The company's research and development efforts are centered on innovative therapeutic approaches for serious medical conditions. Inventiva Sa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventiva Sa stock

Current Liabilities of Inventiva Sa is 85.74 M USD in 2025.

Current Liabilities of Inventiva Sa changed from 132.46 M USD to 85.74 M USD, representing a -35.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Inventiva Sa since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Inventiva Sa historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Inventiva Sa

All Key Metrics — Inventiva Sa